Biogen: What Now?
February 02, 2017 at 17:32 PM EST
With the spin off of its hemophilia drug business in the rear view mirror, how will biotechnology giant Biogen ( BIIB ) fare in the months to come? It was a volatile day for the drug maker’s stock price, which seesawed before closing at $264.23 a share, a better than 1.8% rise, and a number of analysts weighed in on the name.
